



07-26-06

09/892591 Cofc

PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2005		Complete if Known	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Patent Number	7,029,872
TOTAL AMOUNT OF PAYMENT (\$) 100.00		Issue Date	April 18, 2006
		First Named Inventor	Tillman U. Gemgross
		Examiner Name	Celine X. Qian
		Art Unit	1636
		Attorney Docket No.	GFI/100

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify):	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 06-1075
	Deposit Account Name: Fish & Neave IP Group, Ropes & Gray LLP
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
Application Type	Fee (\$)	FILING FEES	SEARCH FEES	EXAMINATION FEES		Fees Paid (\$)	
		Small Entity Fee (\$)	Small Entity Fee (\$)	Small Entity Fee (\$)	Small Entity Fee (\$)		
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
Fee Description						Small Entity Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
- =		x	=		Fee (\$)		Fee Paid (\$)
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
- =		x	=				
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
- 100 =	/50	(round up to a whole number) x		=			
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)						Fees Paid (\$)	
Other (e.g., late filing surcharge): 1811 Certificate of correction						100.00	

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	47,580
Name (Print/Type)	Gloria Fuentes	Telephone	(212) 596-9000
		Date	July 24, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV669635778US, in an envelope addressed to: Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 24, 2006

Signature: (Andrea Silverman)

AUG 01 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV669635778US, in an envelope addressed to: Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 24, 2006

Signature:

(Andrea Silverman)

Docket No.: GFI/100
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Letters Patent of:
Tillman U. Gerngross

Patent No.: 7,029,872

Issued: April 18, 2006

For: METHODS FOR PRODUCING MODIFIED
GLYCOPROTEINS

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.323**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In References Cited, U.S. Patent Documents [56]:

- In "5,602,003", change "Pierce" to --Pierse--.
- In "5,854,018", change "Hitzeman" to --Hitzemane--.
- In "Nikawa", change "conversation" to --conservation--.
- In "Puglielli", change "GDP-fuccose" to --GDP-fucose--.
- In "Romero", change "enzymemic" to --enzymic--.
- In "Schachter", change "453-461 (1991)" to --453-461 (1991)--.
- In "Sikorski", change "of efficient" to --for efficient--.

AUG 01 2006

07/26/2006 SSESHE1 00000042 061075 7029872
01 FC:1811 100.00 DA

In Abstract [57]:

- Change "Thelower" to --The lower--.

In the Specification:

- Col. 1, line 3, please add the following text:

STATEMENT OF FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Phase I SBIR grant no. 1R43GM66690-1 from the National Institute of Health (NIH) and the National Institute of General Medical Sciences (NIGMS) and grant no. 70NANB2H3046 from the National Institute of Standards and Technology Advanced Technology Program (NIST-STP).

- Col. 1, lines 62-63, italicize "Current Opinion in Biotechnology".
- Col. 2, line 28, change "GnT IV GnT V" to --GnT IV, GnT V,--.
- Col. 3, line 45, delete "it" after "albeit".
- Col. 6, line 48, italicize "J. Cell. Biol."
- Col. 7, line 18, change "The" to regular type.
- Col. 7, line 32, change "a-1,2" to -- α -1,2--.
- Col. 8, line 33, change "Thelower" to --The lower--.
- Col. 8, line 36, change "*Hansenulapolymorpha*" to --*Hansenula polymorpha*--.
- Col. 10, line 45, change "mannosylphophate" to --mannosylphosphate--.
- Col. 11, lines 38-40, make into a subsection the words "Inactivation of Fungal Glycosylation Enzymes such as 1,6-mannosyltransferase".
- Col. 12, line 32, change "(2 β)" to --(2 μ)--.
- Col. 12, line 39, change "2 β " to --2 μ --.
- Col. 12, line 47, change "OCHi" to --OCH1--.

- Col. 12, lines 55, change: "can" to --is--.
- Col. 12, line 56, insert --with-- after "which".
- Col. 13, line 18, insert --are-- before "able".
- Col. 13, Table 2, after "ATGGCGAAGGCAGATGGCAGT" insert --(SEQ ID NO:1)--.
- Col. 13, Table 2, after "TTAGTCCTTCCAACCTTCCTTC" insert --(SEQ ID NO:2)--.
- Col. 13, Table 2, after "TAYTGGMGNGTNGARCYNGAYATHAA" insert --(SEQ ID NO:3)--.
- Col. 13, Table 2, after "GCRTCNCCCCANCKYTCRTA" insert --(SEQ ID NO:4)--.
- Col. 15, line 18, italicize "Mouse".
- Col. 15, line 21, italicize "Bacillus".
- Col. 16, Table 4, italicize under "Gene": "Ktrl", "Mns1", "CWH41", and "Kre2".
- Col. 16, line 28, italicize "Homo sapiens".
- Col. 19, Table 5, under "Gene or Sequence", italicize "Mns1", "OCH1", "MNN2", "MNN1", "OCH1", and "Mnt1".
- Col. 19, Table 5, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 20, line 12, italicize "ura3".
- Col. 20, line 33, change "(Gullied et al." to --(Guillen et al.--.
- Col. 21, lines 39-40, change "interferon- α " to --interferon- β --.
- Col. 21, line 57, change "Man5GlcNAc2" to --Man₅GlcNAc₂--.
- Col. 21, line 59, change "supermatants" to --supernatants--.
- Col. 23, line 39, delete "is".
- Col. 23, line 66, change "Beminsone" to --Berninsone--.
- Col. 24, line 19, after "KDEL" insert --(SEQ ID NO:6)--.
- Col. 24, line 19, after "HDEL" insert --(SEQ ID NO:5)--.

- Col. 24, line 25, after "KDEL" insert --(SEQ ID NO:6)--.
- Col. 24, line 25, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 26, line 54, change "265:20863-20688" to --265:20863-20868--.

In the claims:

- Col. 30, line 59, change "." to --,--.
- Col. 31, line 13, change "comprnsing" to --comprising--.
- Col. 32, line 30, change "GLcNAc" to --GlcNAc--.
- Col. 32, line 33, change "Pichiafilandica" to --Pichia finlandica--.
- Col. 32, line 37, change "*pyperi*" to --*pijperi*--.
- Col. 32, line 50, change "OCHi" to --OCH1--.
- Col. 32, line 67, change "*man ihotas*" to --manihotas--.
- Col. 33, line 12, insert --a-- after "or".

Through this Certificate of Correction Patentee is adding to the specification a "Statement of Federally Sponsored Research." The omission of this information from the originally filed application was inadvertent. The other errors now sought to be corrected are inadvertent typographical errors, the correction of which does not involve new matter or require reexamination.

Some of the typographical errors were incurred through the fault of the Patent and Trademark Office, while others were incurred through the fault of the Patentee. Accordingly, please charge our Deposit Account No. 06-1075 in the amount of \$100.00 covering the fee set forth in 37 CFR 1.20(a).

Enclosed herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to Deposit Account No. 06-1075, under Order No. GFI/100. A duplicate copy of this paper is enclosed.

Dated: July 24, 2006

Respectfully submitted,

By 

Gloria Fuentes

Registration No.: 47,580

ROPES & GRAY LLP

1251 Avenue of the Americas

New York, New York 10020-1104

(212) 596-9000

(212) 596-9090 (Fax)

Attorneys/Agents For Applicant

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV669635778US, in an envelope addressed to: Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 24, 2006

Signature:

Andrea Silverman
(Andrea Silverman)



Docket No.: GFI/100
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Tillman U. Gerngross

Patent No.: 7,029,872

Issued: April 18, 2006

For: METHODS FOR PRODUCING MODIFIED
GLYCOPROTEINS

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.323**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In References Cited, U.S. Patent Documents [56]:

- In "5,602,003", change "Pierce" to --Pierse--.
- In "5,854,018", change "Hitzeman" to --Hitzemane--.
- In "Nikawa", change "conversation" to --conservation--.
- In "Puglielli", change "GDP-fuccose" to --GDP-fucose--.
- In "Romero", change "enzymemic" to --enzymic--.
- In "Schachter", change "453-461) (1991)" to --453-461 (1991)--.
- In "Sikorski", change "of efficient" to --for efficient--.

In Abstract [57]:

- Change "Thelower" to --The lower--.

In the Specification:

- Col. 1, line 3, please add the following text:

STATEMENT OF FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Phase I SBIR grant no. 1R43GM66690-1 from the National Institute of Health (NIH) and the National Institute of General Medical Sciences (NIGMS) and grant no. 70NANB2H3046 from the National Institute of Standards and Technology Advanced Technology Program (NIST-STP).

- Col. 1, lines 62-63, italicize "Current Opinion in Biotechnology".
- Col. 2, line 28, change "GnT IV GnT V" to --GnT IV, GnT V,--.
- Col. 3, line 45, delete "it" after "albeit".
- Col. 6, line 48, italicize "J. Cell. Biol."
- Col. 7, line 18, change "The" to regular type.
- Col. 7, line 32, change "a-1,2" to -- α -1,2--.
- Col. 8, line 33, change "Thelower" to --The lower--.
- Col. 8, line 36, change "*Hansenulapolymorpha*" to --*Hansenula polymorpha*--.
- Col. 10, line 45, change "mannosylphophate" to --mannosylphosphate--.
- Col. 11, lines 38-40, make into a subsection the words "Inactivation of Fungal Glycosylation Enzymes such as 1,6-mannosyltransferase".
- Col. 12, line 32, change "(2 β)" to --(2 μ)--.
- Col. 12, line 39, change "2 β " to --2 μ --.
- Col. 12, line 47, change "OCHi" to --OCH1--.

- Col. 12, lines 55, change: "can" to --is--.
- Col. 12, line 56, insert --with-- after "which".
- Col. 13, line 18, insert --are-- before "able".
- Col. 13, Table 2, after "ATGGCGAAGGCAGATGGCAGT" insert --(SEQ ID NO:1)--.
- Col. 13, Table 2, after "TTAGTCCTTCCAACCTTCCTTC" insert --(SEQ ID NO:2)--.
- Col. 13, Table 2, after "TAYTGGMGNGTNGARCYNGAYATHAA" insert --(SEQ ID NO:3)--.
- Col. 13, Table 2, after "GCRTCNCCCCANCKYTCRTA" insert --(SEQ ID NO:4)--.
- Col. 15, line 18, italicize "Mouse".
- Col. 15, line 21, italicize "Bacillus".
- Col. 16, Table 4, italicize under "Gene": "Ktr1", "Mns1", "CWH41", and "Kre2".
- Col. 16, line 28, italicize "Homo sapiens".
- Col. 19, Table 5, under "Gene or Sequence", italicize "Mns1", "OCH1", "MNN2", "MNN1", "OCH1", and "Mnt1".
- Col. 19, Table 5, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 20, line 12, italicize "ura3".
- Col. 20, line 33, change "(Gullied et al." to --(Guillen et al.--.
- Col. 21, lines 39-40, change "interferon- α " to --interferon- β --.
- Col. 21, line 57, change "Man5GlcNAc2" to --Man₅GlcNAc₂--.
- Col. 21, line 59, change "supermatants" to --supernatants--.
- Col. 23, line 39, delete "is".
- Col. 23, line 66, change "Beminsone" to --Berninsone--.
- Col. 24, line 19, after "KDEL" insert --(SEQ ID NO:6)--.
- Col. 24, line 19, after "HDEL" insert --(SEQ ID NO:5)--.

- Col. 24, line 25, after "KDEL" insert --(SEQ ID NO:6)--.
- Col. 24, line 25, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 26, line 54, change "265:20863-20688" to --265:20863-20868--.

In the claims:

- Col. 30, line 59, change "." to --,--.
- Col. 31, line 13, change "comprnsing" to --comprising--.
- Col. 32, line 30, change "GLcNAc" to --GlcNAc--.
- Col. 32, line 33, change "Pichiafilandica" to --Pichia finlandica--.
- Col. 32, line 37, change "pyperi" to --pimper--.
- Col. 32, line 50, change "OCHi" to --OCH1--.
- Col. 32, line 67, change "*man ihotas*" to --manihotas--.
- Col. 33, line 12, insert --a-- after "or".

Through this Certificate of Correction Patentee is adding to the specification a "Statement of Federally Sponsored Research." The omission of this information from the originally filed application was inadvertent. The other errors now sought to be corrected are inadvertent typographical errors, the correction of which does not involve new matter or require reexamination.

Some of the typographical errors were incurred through the fault of the Patent and Trademark Office, while others were incurred through the fault of the Patentee. Accordingly, please charge our Deposit Account No. 06-1075 in the amount of \$100.00 covering the fee set forth in 37 CFR 1.20(a).

Enclosed herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to Deposit Account No. 06-1075, under Order No. GFI/100. A duplicate copy of this paper is enclosed.

Dated: July 24, 2006

Respectfully submitted,

By 

Gloria Fuentes

Registration No.: 47,580
ROPES & GRAY LLP
1251 Avenue of the Americas
New York, New York 10020-1104
(212) 596-9000
(212) 596-9090 (Fax)
Attorneys/Agents For Applicant

GFI/100

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,029,872
APPLICATION NO. : 09/892,591
ISSUE DATE : April 18, 2006
INVENTOR(S) : Tillman U. Gerngross

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In References Cited, U.S. Patent Documents [56]:

- In "5,602,003", change "Pierce" to --Pierse--.
- In "5,854,018", change "Hitzeman" to --Hitzemane--.
- In "Nikawa", change "conversation" to --conservation--.
- In "Puglielli", change "GDP-fuccose" to --GDP-fucose--.
- In "Romero", change "enzymemic" to --enzymic--.
- In "Schachter", change "453-461) (1991)" to --453-461 (1991)--.
- In "Sikorski", change "of efficient" to --for efficient--.

In Abstract [57]:

- Change "Thelower" to --The lower--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Gloria Fuentes
ROPES & GRAY LLP
1251 Avenue of the Americas
New York, New York 10020-1104

AUG 01 2006

In the Specification:

- Col. 1, line 3, please add the following text:

STATEMENT OF FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Phase I SBIR grant no. 1R43GM66690-1 from the National Institute of Health (NIH) and the National Institute of General Medical Sciences (NIGMS) and grant no. 70NANB2H3046 from the National Institute of Standards and Technology Advanced Technology Program (NIST-STP).

- Col. 1, lines 62-63, italicize "Current Opinion in Biotechnology".
- Col. 2, line 28, change "GnT IV GnT V" to --GnT IV, GnT V,--.
- Col. 3, line 45, delete "it" after "albeit".
- Col. 6, line 48, italicize "J. Cell. Biol."
- Col. 7, line 18, change "The" to regular type.
- Col. 7, line 32, change "a-1,2" to -- α -1,2--.
- Col. 8, line 33, change "Thelower" to --The lower--.
- Col. 8, line 36, change "*Hansenulapolyomorpha*" to --*Hansenula polymorpha*--.
- Col. 10, line 45, change "mannosylphosphate" to --mannosylphosphate--.
- Col. 11, lines 38-40, make into a subsection the words "Inactivation of Fungal Glycosylation Enzymes such as 1,6-mannosyltransferase".
- Col. 12, line 32, change "(2 β)" to --(2 μ)--.
- Col. 12, line 39, change "2 β " to --2 μ --.
- Col. 12, line 47, change "OCHi" to --OCH1--.
- Col. 12, lines 55, change: "can" to --is--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Gloria Fuentes
ROPES & GRAY LLP
1251 Avenue of the Americas
New York, New York 10020-1104

AUG 01 2006

- Col. 12, line 56, insert --with-- after "which".
- Col. 13, line 18, insert --are-- before "able".
- Col. 13, Table 2, after "ATGGCGAAGGCAGATGGCAGT" insert --(SEQ ID NO:1)--.
- Col. 13, Table 2, after "TTAGTCCTTCCAACCTTCCTTC" insert --(SEQ ID NO:2)--.
- Col. 13, Table 2, after "TAYTGGMGNGTNGARCYNGAYATHAA" insert --(SEQ ID NO:3)--.
- Col. 13, Table 2, after "GCRTCNCCCCANCKYTCRTA" insert --(SEQ ID NO:4)--.
- Col. 15, line 18, italicize "Mouse".
- Col. 15, line 21, italicize "Bacillus".
- Col. 16, Table 4, italicize under "Gene": "Ktrl", "Mns1", "CWH41", and "Kre2".
- Col. 16, line 28, italicize "Homo sapiens".
- Col. 19, Table 5, under "Gene or Sequence", italicize "Mns1", "OCH1", "MNN2", "MNN1", "OCH1", and "Mnt1".
- Col. 19, Table 5, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 20, line 12, italicize "ura3".
- Col. 20, line 33, change "(Gullied et al." to --(Guillen et al.--.
- Col. 21, lines 39-40, change "interferon- α " to --interferon- β --.
- Col. 21, line 57, change "Man5GlcNAc2" to --Man₅GlcNAc₂--.
- Col. 21, line 59, change "supermatants" to --supernatants--.
- Col. 23, line 39, delete "is".
- Col. 23, line 66, change "Beminsone" to --Berninsone--.
- Col. 24, line 19, after "KDEL" insert --(SEQ ID NO:6)--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Gloria Fuentes
 ROPES & GRAY LLP
 1251 Avenue of the Americas
 New York, New York 10020-1104

- Col. 24, line 19, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 24, line 25, after "KDEL" insert --(SEQ ID NO:6)--.
- Col. 24, line 25, after "HDEL" insert --(SEQ ID NO:5)--.
- Col. 26, line 54, change "265:20863-20688" to --265:20863-20868--.

In the claims:

- Col. 30, line 59, change "." to --,--.
- Col. 31, line 13, change "comprnsing" to --comprising--.
- Col. 32, line 30, change "GLcNAc" to --GlcNAc--.
- Col. 32, line 33, change "Pichiafilandica" to --Pichia finlandica--.
- Col. 32, line 37, change "pyperi" to --pijperi--.
- Col. 32, line 50, change "OCHi" to --OCH1--.
- Col. 32, line 67, change "*man ihotas*" to --manihotas--.
- Col. 33, line 12, insert --a-- after "or".

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Gloria Fuentes
ROPES & GRAY LLP
1251 Avenue of the Americas
New York, New York 10020-1104

AUG 01 2006